1. C 60 -based Multivalent Glycoporphyrins Inhibit SARS-CoV-2 Specific Interaction with the DC-SIGN Transmembrane Receptor.
- Author
-
Patino-Alonso J, Cabrera-González J, Merino J, Nieto-Ortiz G, Lasala F, Katati J, da Cruz CHB, Monnappa AK, Mateos-Gil P, Canales Á, López-Montero I, Illescas BM, Delgado R, and Martín N
- Subjects
- Humans, COVID-19 virology, COVID-19 Drug Treatment, Molecular Dynamics Simulation, Protein Binding, Spike Glycoprotein, Coronavirus metabolism, Spike Glycoprotein, Coronavirus chemistry, Cell Adhesion Molecules metabolism, Cell Adhesion Molecules antagonists & inhibitors, Fullerenes chemistry, Fullerenes pharmacology, Lectins, C-Type metabolism, Lectins, C-Type antagonists & inhibitors, Porphyrins chemistry, Porphyrins pharmacology, Receptors, Cell Surface metabolism, Receptors, Cell Surface antagonists & inhibitors, SARS-CoV-2 drug effects, SARS-CoV-2 metabolism
- Abstract
Since WHO has declared the COVID-19 outbreak a global pandemic, nearly seven million deaths have been reported. This efficient spread of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is facilitated by the ability of the spike glycoprotein to bind multiple cell membrane receptors. Although ACE2 is identified as the main receptor for SARS-CoV-2, other receptors could play a role in viral entry. Among others, C-type lectins such as DC-SIGN are identified as efficient trans-receptor for SARS-CoV-2 infection, so the use of glycomimetics to inhibit the infection through the DC-SIGN blockade is an encouraging approach. In this regard, multivalent nanostructures based on glycosylated [60]fullerenes linked to a central porphyrin scaffold have been designed and tested against DC-SIGN-mediated SARS-CoV-2 infection. First results show an outstanding inhibition of the trans-infection up to 90%. In addition, a deeper understanding of nanostructure-receptor binding is achieved through microscopy techniques, high-resolution NMR experiments, Quartz Crystal Microbalance experiments, and molecular dynamic simulations., (© 2023 The Authors. Small published by Wiley‐VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF